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1. Introduction 
The purpose of a classification is not only to 
group diseases with the same biological character- 
istics, but also to get insight into the pathogenesis 
and to define subgroups with different prognoses and 
different therapeutic approaches. In acute leukaemias 
the classification now most widely used is the 
French-American-British (FAB) classification as 
proposed in 1976, which was based on morphology 
and cytochemistry [l]. The FAB group felt that 
discrimination of myeloblasts from lymphoblasts on 
morphological characteristics only was insufficient. 
For this reason they proposed to define the differ- 
ence between acute myeloid leukaemia @ML) and 
acute lymphoblastic leukaemia (ALL) by the positiv- 
ity or negativity respectively of the blasts for the 
myeloperoxidase (MPO) or Sudan B Black reaction. 
Within acute myeloid leukaemia 6 categories were 
discriminated (Ml-M61 by morphology and the use 
of o-naphthyl acetate esterase (ANAE) to discrimi- 
nate monoblasts from myeloblasts [ 1,2]. 
Later, immunological markers were used to define 
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two new subtypes in acute myeloid leukaemia, the 
acute leukaemia with minimal myeloid differentia- 
tion (AML-MO) and the megakaryoblastic leukaemia 
(AML-M7), both being Sudan B Black negative but 
not lymphoblastic (Table 1) [3-51. Immunological 
marker analysis, however, was not introduced into 
the FAB classification for ALL, even when the 
subdivision of the acute lymphoblastic leukaemias 
into Ll and L2, merely based on the size of the 
blasts, showed very little relevance to their biological 
features and prognosis [ 1,7]. Immunological marker 
analysis is pivotal in the classification of ALL. In 
this way not only the distinction between T and B 
lineage ALL can be made, but also distinct sub- 
groups within these categories can be defined which 
are of biological and prognostic relevance [8,9]. The 
definition of L3, morphologically distinct from Ll 
and L2, and also with a typical immunological phe- 
notype is overruled by the presence of a transloca- 
tion of the MYC oncogene located on the long arm 
of chromosome 8 to either the immunoglobulin 
heavy-chain gene on chromosome 14 (t(8;14)) or to 
one of the light-chain genes on chromosome 2 or 22 
(t(2;8) or t(8;22)) in nearly 100% of cases [lo-121. 
The question then arises with respect to AML 
which on morphological and cytochemical grounds 
is much more differentiated than ALL, what im- 
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Table 1 
Summary of the FAB classification of AML 
FAB subtype Definition 
MO 
Ml 
M2 
< 3% SBB + * blasts, My-t- * *, Ly- * * * 
> 90% blasts 
30-90% blasts 
> 10% myeloid cells 
< 20% monocytoid cells 
M3 majority promyelocytes 
hypergranular 
M3V 
M4 
microgranular 
> 20% mature myeloid cells and 
> 20% ANAE+ * * * * blasts 
> 5 x 109/1 monocytes in the blood 
M5 
M6 
> 80% monocytoid cells 
> 50% nucleated erythroid cells 
> 30% blasts of myeloid cells of the 
non erytbroid population 
M7 < 3% SBB + blasts 
> 30% megakaryoblasts defined by CD41/CD61 
or electron microscopy with platelet peroxidase 
* Sudan Black B. 
* * Myeloid markers positive (CD13, CD33, myeloperoxidase, 
CDw65). 
* * * Lymphoid markers negative (CD3, CD.5, CDlO, CD19). 
* * * * a-Naphthyl acetate esterase. 
munological markers and cytogenetic analysis may 
contribute to the characteristics of the different sub- 
types. 
2. Concordance 
Essential to any classification is an acceptable 
level of reproducibility between observers. In the 
FAB classification the introduction of cytochemistry 
contributed to concordance compared to morphology 
alone, as did the definition of quantitative criteria for 
acute leukaemias, for instance, to distinguish acute 
myeloid leukaemias from the myelodysplastic syn- 
dromes [1,2,13]. But even then the reproducibility 
between observers varies from 45.7 to 86.8% [14- 
181. Review of AML bone marrow smears by the 
Dutch Slide Review Committee of Adult Leukaemias 
gives about 80% agreement. Most problems arise in 
discrimination between Ml and M2 and between M2 
and M4 [19]. The addition of immunophenotyping to 
morphology and cytochemistry improves agreement 
between independent observers, although the estima- 
tion of Browman et al. who described an improve- 
ment to 99% seems fairly optimistic [141. 
3. Correlation between FAB subtypes and im- 
munological phenotype 
Immunophenotyping can be helpful in confirming 
the diagnosis of AML and is indispensable in differ- 
entiating AML-MO and AML-M7 from ALL (Table 
1) [3-61. For discrimination between myeloid 
leukaemias (Ml-M3) and monocytic leukaemias (M4, 
M5) CD14 shows some correlation with monocytic 
leukaemias but is not very sensitive, being negative 
in the early monoblastic leukaemias [20,21]. Because 
distinct myeloid differentiation antigens are lacking, 
no further discrimination can be made immunologi- 
cally between Ml and M2 than by the quantitative 
criteria of the FAB classification [19]. AML-M3, 
morphologically divided into two subtypes (hyper- 
granular and hypogranular), both strongly positive 
for the myeloperoxidase reaction, shows a typical 
immunological pattern (CD13 + , CD33 + , CD9 + , 
CD68 + , CD34 - , HLA-DR - , CD15 - >, but this 
pattern gives little additional information to a classi- 
fication as the morphology itself is very characteris- 
tic and cytogenetic analysis is definite [22,23]. 
4. Correlation between FAB subtypes and kary- 
otype 
Some chromosomal abnormalities are correlated 
to certain AML FAB subtypes and are of prognostic 
importance (Table 2). No specific chromosomal pat- 
tern was found in AML-MO in different recent stud- 
Table 2 
Chromosomal translocations FAB Relative 
classification prognosis 
t(8;21Xq22;q22) M2 fair to good 
t(15;17)(q22;q21) M3 fair to good 
inv(l6Xpl3:q22)/t(l6;16) M4eo good 
(pl3;q22) 
t(9;1 l)(p21;q23) M5 poor 
t(1 lq23) M4-M5 poor 
t(6;9Xp23;q34) M2, M4 poor 
t(8;16)(pll;p13) M5 undetermined 
inv(3Xq2l;q26)/t(3;33) M4 undetermined 
t(1;3Xp36;q21) 
t(1;22Xp13;q13) M7 undetermined 
ies 124-271. In contrast, a higher frequency of abnor- 
mal karyotypes, complex karyotypes and unbalanced 
chromosomal changes (-5/5q- and/or -7/7q- and 
+ 13) compared with AML-Ml were observed by 
Cunea et al. in a large study of 26 patients, which 
may partly account for the very poor outcome in 
these patients [28]. Ninety percent of the patients 
whose leukaemia shows t(8;21 )(q22;q22) have 
AML-M2. This subtype has a better prognosis than 
other subtypes [29]. In contrast, many leukaemias 
categorized as M2 have other or no cytogenetic 
abnormalities and may be derived from transformed 
myelodysplastic syndromes or early diagnosed 
AML-Ml having less than 30% blasts but with a 
maturing granulocytic component like AML-M2. As 
stated, virtually all promyelocytic leukaemias (M3) 
have t( 15; 17)(q22;q2 1). Hence one should reconsider 
the M3 classification if t(15; 17) cannot be demon- 
strated. This subtype, clinically characterized by its 
bleeding tendency, needs special treatment with 
retinoid acid and has a better prognosis than the 
other subtypes [30]. The good prognostic 
inv( 16)(pl3q22) is associated with the diagnosis of 
M4 EO [31]. Common translocations such as 
t(6;l l)(q26q23), t(9;l l)(p21;q23) and t(1 1;19) 
(q23;p13) are found in monocytic leukaemias [29]. In 
acute myeloid leukaemia originating from myelodys- 
plastic syndrome -5/5q- or -7/7q- is frequently 
found, and has a poor prognosis [32]. Complex kary- 
otypic abnormalities are also associated with a poor 
prognosis [31]. Thus, to define the prognosis of 
certain AML subtypes. cytogenetic analysis IS indis- 
pensable. 
5. Differentiation between MDS and AMI. 
The discrimination between AML and refractory 
anaemia with excess of blasts in transformation 
(RAEB-t) is based on the limit of 30% of nucleated 
bone marrow cells being blasts for the latter [ 1,2,13]. 
This 30% limit is arbitrary and with this limit not all 
cases of acute leukaemias will be recognized. For 
example, patients with de noco AML with a rapidly 
rising blast count but less than 30% blasts will not be 
regarded as having acute myeloid leukaemia. Im- 
munophenotyping makes no contribution in distin- 
guishing between AML and MDS, but cytogenetical 
analysis will add important information. In dr now) 
AML translocations are often found; in the 
myelodysplastic syndromes, on the other hand, nu- 
meric chromosomal abnormalities such as -5/5q-, 
-7/7q- or t-8 are more frequently observed [32- 
341. 
6. Sudan B Black negative acute leukaemias 
Following the FAB classification, Sudan B Black 
negative acute leukaemias are of myeloid (MO), 
megakaryocytic (M7) or lymphoblastic origin (ALL) 
[3-51. However, there are some other Sudan B Black 
Table 3 
Definition of subtypes in Sudan B Black negative leukaemias 
Subtypes Immunophenotype 
ALL Ly+ =** 
AML M7 CD41 and/or CD42 and/or CD61 
AML MO My+ **‘*,Ly- ****=, 
AEL ’ no lineage markers available 
AUL * ’ MY- *“****.LY- 
SBB negative biphenotypic AL My+,Ly+ 
CD34 + , HLA-DR + 
(CD34 + , HLA-DR + ) 
(CD34 + , HLA-DR + ) 
(CD34 + , HLA-DR + ) 
’ AEL = hypothetical acute erythroblastic leukaemia (less differentiated than AML-M6). 
* * AUL = acute undifferentiated leukaemia. 
’ ’ - Lymphoid markers positive (CD3, CD22, CD79a). 
* * * * Myeloid markers positive (CD13, CD33, myeloperoxidase, CDw65, CD1 17). 
’ * ” * * Lymphoid markers negative. 
’ ’ * * * * Myeloid markers negative. 
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negative acute leukaemias not described in the FAB 
classification such as acute undifferentiated 
leukaemia (AUL) and acute erythroblastic leukaemia 
(Table 3). Without immunophenotyping the classifi- 
cation of acute undifferentiated leukaemia is impos- 
sible [35,36]. For the hypothetical early erythroblas- 
tic leukaemias no early erythroid markers are avail- 
able so far. Most often the undifferentiated or mini- 
mally differentiatied leukaemias are CD34 + [24- 
26,35,36]. It is not known if cytogenetical analysis 
adds more information in these subtypes. 
7. Biphenotypic and bilineage acute leukaemias 
In the FAB classification there is a strict discrimi- 
nation between acute myeloid leukaemia and acute 
lymphoblastic leukaemia. However, a small subset of 
leukaemias (less than 5%) consist of leukaemic cells 
expressing markers of both myeloid and lymphoid 
lineage (biphenotypic leukaemias) or consist of two 
different populations of cells each expressing differ- 
ent markers (bilineage acute leukaemias) [3,38]. 
Markers expressed on more than 20% of the blasts 
are considered positive, except for TdT (more than 
10% expression). Here, the FAB classification is 
lacking and immunophenotyping is essential for the 
recognition of these types of leukaemias. Catovsky et 
al. proposed a scoring system to distinguish bipheno- 
typing acute leukaemias from acute leukaemias with 
aberrant expression, using immunophenotyping and 
rearrangement of the B or T-cell receptor [3,37]. This 
scoring system has recently been updated by the 
European Group for Immunophenotyping of 
Leukaemias (EGIL) [38]. Prognosis and choice of 
treatment are difficult to determine since larger stud- 
ies are never published, but the prognosis seems very 
poor. 
8. Prognostic value of the FAB classification 
In AML, some differences in prognosis are seen 
between the different AML FAB subtypes. AML-MO 
has a worse outcome than all other subtypes of AML 
[24,26-281. Ml shows a lower remission rate than 
M2 and M4. M3 has a much better prognosis than 
the other subtypes. M5, M6 and M7 show a lower 
remission rate [19,39]. Immunophenotyping is of no 
prognostic value. Studies on the prognostic value of 
CD34 expression are inconclusive, as is CD7 expres- 
sion [40-431. The prognosis for the different FAB 
subtypes is best correlated with characteristic cytoge- 
netic abnormalities-e.g., t(15;17), t(8;21), inv(l6) 
or del(16) (Table 21 [29-311. 
9. Conclusions 
The FAB classification is a good guide to classi- 
fying AML, on the basis of morphologically recog- 
nizable criteria, but is insufficient for the recognition 
of undifferentiated leukaemias, Sudan B Black nega- 
tive non-lymphoblastic leukaemias, biphenotypic and 
bilineage leukaemias, and certain important sub- 
groups like t(8;21) in AML-M2. Immunophenotyp- 
ing and cytogenetics are therefore indispensable. An 
attempt to integrate morphological, immunological 
and cytogenetic methods into a new classification 
was made by the MIC Cooperative Study Group 
(Table 4), but so far only 10 categories have been 
defined, which means that not all acute myeloid 
leukaemias can be categorised in this classification 
1441. 
In addition, several new techniques can make 
important contributions to the diagnosis and monitor- 
ing of acute leukaemias. Fluorescent in situ hy- 
bridization (FISH) can be routinely used to identify 
specific chromosomes involved in chromosome 
Table 4 
The MIC classification of AML 
Karyotypic change Morphology (FAB) Suggested MIC 
nomenclature 
t(8;21Xq22;q22) M2 M2/t(8;21) 
t(15;17Xq22;q12) M3, M3v M3/t(15;17) 
t/del/(l lXq23) M5a(M5b, M4) MSa/t(l lq) 
inv/de1(16Xq22) M4Eo M4Eo/inv(l6) 
(9;22Xq34;qll) Ml(M2) Ml/d9;22) 
t(6;9Xp21-22;q34) M2 or M4 with M2/d6;9) 
basophilia 
inv(3)(q21q26) Ml(M2, M4, M7) with Ml/inv(3) 
thrombocytosis 
t(8;16Xpll;p13) M5b with phagocytosis M5b/t(8;16) 
t/del(l2Xpll-13) M2 with basophilia M2 Baso/t(l2p) 
f4 M4(M2) M4/+4 
translocations [45,46]. More cells can be observed 
than with cytogenetic analysis and it is not restricted 
to cells in metaphasis. Direct correlation of chromo- 
somal abnormalities with morphology or immuno- 
logical markers is possible by this technique [47,48]. 
The polymerase chain reaction (PCR) is used as a 
fast and reliable technique to detect chromosomal 
re-arrangements, e.g., t(8;2 1) and t(l5; 17). at diagno- 
sis and can be used for the detection of minimal 
residual disease after treatment due to its high sensi- 
tivity [49-511. 
Expression of P-glycoprotein, a protein associated 
with multidrug resistance and treatment failure, may 
be of prognostic significance [52,53]. 
Thus, the FAB classification is not outdated for 
the diagnosis of AML, but it does require other 
procedures for refinement of the diagnosis and deter- 
mination of the prognosis. This classification re- 
mains an important cornerstone of a ‘combined 
modality’ classification of the acute myeloid 
leukaemias. 
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